Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 with standard adjuvant therapy in resected digestive system neoplasms
NCT06026774Phase 1Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2023
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-R01 in cholangiocarcinoma (CCA), pancreatic cancer (PC), hepatocellular carcinoma (HCC) and 2 more, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Number of Participants with Adverse Events. Started Sep 2023; status: recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
cholangiocarcinoma (CCA)pancreatic cancer (PC)hepatocellular carcinoma (HCC)gastric cancer (GC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT06026774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026774.